

# Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists

Giorgia Pastorin <sup>a</sup>, Chiara Bolcato <sup>a</sup>, Barbara Cacciari <sup>b</sup>, Sonja Kachler <sup>c</sup>, Karl-Norbert Klotz <sup>c</sup>, Christian Montopoli <sup>d</sup>, Stefano Moro <sup>d,\*</sup>, Giampiero Spalluto <sup>a,\*</sup>

<sup>a</sup> Dipartimento di Scienze Farmaceutiche, Università di Trieste, Piazzale Europa 1, I-34127, Trieste, Italy

<sup>b</sup> Dipartimento di Scienze Farmaceutiche, Università degli Studi di Ferrara, Via Fossato di Mortara 17-19, I-44100 Ferrara, Italy

<sup>c</sup> Institut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Str. 9, D-97078 Würzburg, Germany

<sup>d</sup> Molecular Modeling Section, Dipartimento di Scienze Farmaceutiche, Università di Padova, via Marzolo 5, I-35131 Padova, Italy

Received 20 November 2004; received in revised form 12 January 2005; accepted 15 January 2005

Available online 23 March 2005

## Abstract

A new series of potential adenosine receptor antagonists with a [1,2,4]-triazolo-[3,4-f]-purine structure have been synthesized, and their affinities at the four adenosine receptor subtypes ( $A_1$ ,  $A_{2A}$ ,  $A_{2B}$  and  $A_3$ ) have been evaluated. The design was based on the demonstrated approach to novel  $A_3$  adenosine receptor antagonists of adding a third ring to the xanthine structure. Unfortunately, all the synthesized compounds were completely inactive at all four adenosine receptor subtypes independently of their substitutions. Preliminary molecular modeling investigation has demonstrated that only a low degree of steric and electrostatic complementarity has been observed for all the new synthesized triazolo-purines with respect to other structurally related  $A_3$  receptor antagonists. This analysis yielded valuable information about structure–activity relationships and further design of potential adenosine receptor antagonists.

© 2005 Elsevier SAS. All rights reserved.

**Keywords:** Adenosine receptors; Antagonists; Xanthine; G-protein-coupled receptors; Cycloaddition

## 1. Introduction

Adenosine is a widely distributed modulator, which, interacting with four different receptor subtypes named  $A_1$ ,  $A_{2A}$ ,  $A_{2B}$  and  $A_3$ , respectively, induces a wide range of physiological effects [1,2]. All these receptor subtypes are coupled to G-protein and while activation of  $A_1$  and  $A_3$  produces a decrease of cAMP level, the stimulation of  $A_{2A}$  or  $A_{2B}$  adenosine receptors gives the opposite effect [3–6].

In recent decades much effort has been devoted to characterize pharmacologically these receptors through the synthesis of potent and selective agonists and/or antagonists. While this goal has been achieved for  $A_1$ ,  $A_{2A}$  and  $A_3$  receptors, due

to the lack of selective ligands, the patho-physiological role of the  $A_{2B}$  adenosine receptor is still under investigation [7,8].

Xanthines (e.g., caffeine, theophylline), which are naturally occurring antagonists for adenosine receptors, have represented the starting point in the search for potent and selective antagonists for the four different adenosine receptor subtypes. In particular, an optimization of substitutions at the 1-, 3-, and 8-positions led to the discovery of potent and selective antagonists for the various adenosine receptor subtypes. (Fig. 1) In particular, while substitution at the 8-position with alkyl (1) [9], styryl (2) [10], or bulky aryl substituents (3) [11,12] permitted to obtain  $A_1$ ,  $A_{2A}$  and  $A_{2B}$  adenosine receptor antagonists (1–3), while analogs constrained between the 7- and 8- (4) [13], or the 3- and 4-positions (5) [14], led to the discovery of appealing  $A_3$  antagonists.

With the aim to identify new lead compounds as adenosine receptor antagonist, we focused our attention on a new modification of the xanthine core designing a new fused tria-

\* Corresponding authors. Prof. Giampiero Spalluto.

Tel.: +39 0405583726; fax: +39 040 52572. Stefano Moro, Ph. D.

Tel.: +39 0498275704; fax: +39 0498275366/704.

E-mail addresses: [spalluto@units.it](mailto:spalluto@units.it) (G. Spalluto); [stefano.moro@unipd.it](mailto:stefano.moro@unipd.it) (S. Moro).





Fig. 1. Structures of xanthine derivatives as potent and selective adenosine receptor antagonists.

zolo nucleus between 7- and 8-position of theophylline structure. (**6**)



In particular, the presence at the 8-position of a phenyl ring substituted at the *para* position with an amino function could permit to link different appendages, in fact as previously described, while small substituents could be appealing for A<sub>2A</sub> and/or A<sub>3</sub> affinity, whereas bulky substituent could be optimal for A<sub>2B</sub> activity.

## 2. Chemistry

The designed compounds **6a-l** have been prepared by one-pot cycloaddition reaction between 8-substituted theophylline and an appropriate hydrazonoyl halide [15,16] as reported in the literature [17]. In fact by reacting at reflux (10 h), in presence of triethylamine, the 8-nitrotheophylline **7** [18–20] with the *N*-(2-bromo-4-nitrophenyl)acetohydrazonoyl bromide **8** [21], the corresponding cycloadduct **6a** was obtained in a good yield [17]. The latter was then reduced with hydrazine in the presence of C/Pd 10% [22] to afford the corresponding amino derivative **6b**, which was reacted in dioxane at room temperature, in the presence of an equivalent amount of triethylamine, with an appropriate acyl chloride **9a-j** to yield the final compounds. (Scheme 1)

Table 1

Activity of synthesized compounds (**6a-j**) at rA<sub>1</sub>, rA<sub>2A</sub>, hA<sub>2B</sub> and hA<sub>3</sub> adenosine receptor subtypes

**6a-l**

Compd.	R	rA <sub>1</sub> <sup>a</sup> % displ. (10 M)	RA <sub>2A</sub> <sup>b</sup> % displ. (10 M)	hA <sub>2B</sub> <sup>c</sup> EC <sub>50</sub> (M)	hA <sub>3</sub> <sup>d</sup> % displ. (10 M)
<b>6a</b>	NO <sub>2</sub>	<10%	<10%	>100	ND
<b>6b</b>	NH <sub>2</sub>	<10%	56 ± 19%	>30	<10%
<b>6c</b>	NHCOCH <sub>2</sub> Ph	<10%	<10%	>30	<10%
<b>6d</b>	NHCOCHPh <sub>2</sub>	<10%	<10%	>30	ND
<b>6e</b>	NHCOCH <sub>3</sub>	<10%	<10%	>100	ND
<b>6f</b>	NHCOPh	<10%	<10%	>100	ND
<b>6g</b>	NHCO-4-OCH <sub>3</sub> -Ph	<10%	<10%	>30	<10%
<b>6h</b>	NHCO(CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>	<10%	<10%	>30	ND
<b>6i</b>	NHCO(CH <sub>2</sub> ) <sub>4</sub> CH <sub>3</sub>	<10%	<10%	>30	ND
<b>6j</b>	NHCOPh-4-Ph	<10%	<10%	>30	<10%
<b>6k</b>	NHCO-Adamantyl	<10%	<10%	>30	ND
<b>6l</b>	NHCO-2-Thienyl	<10%	<10%	>30	ND

ND = not determined.

<sup>a</sup> Displacement of specific [<sup>3</sup>H]R-PIA binding (A<sub>1</sub>) in rat brain membranes.

<sup>b</sup> Displacement of specific [<sup>3</sup>H]CGS 21680 binding (A<sub>2A</sub>) in rat striatal membranes.

<sup>c</sup> Measurement of adenylyl cyclase activity in CHO cells stably transfected with human recombinant A<sub>2B</sub> adenosine receptor, expressed as EC<sub>50</sub> (μM).

<sup>d</sup> Displacement of specific [<sup>125</sup>I]AB-MECA binding at rat A<sub>3</sub> receptors expressed in HEK-293 cells.

Download English Version:

<https://daneshyari.com/en/article/8993411>

Download Persian Version:

<https://daneshyari.com/article/8993411>

[Daneshyari.com](https://daneshyari.com)